Point72 Middle East FZE’s Humacyte HUMA Stock Holding History

Point72 Middle East FZE’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,194	Closed	-$6.74K	–	1879
2022 Q4	$6.74K	Buy	+3,194	New	+$9.7K	﹤0.01%	1760

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Imprint Wealth Mount Pleasant, South Carolina $21.9M AUM

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Point72 Middle East FZE's HUMA Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Humacyte (HUMA) in Q1 2023, closing a stake of 3,194 shares — an estimated $6.74K sold.

Point72 Middle East FZE first reported a position in HUMA in Q4 2022 and held it in 1 quarter. The position peaked at $6.74K in Q4 2022. 69 funds tracked by Wall St. Rank hold HUMA as of Q1 2023.

Point72 Middle East FZE reported no remaining Humacyte position as of Q1 2023 after selling out during the quarter.
Point72 Middle East FZE sold 3,194 Humacyte shares in Q1 2023, an estimated $6.74K.
Point72 Middle East FZE first reported a position in Humacyte in Q4 2022 and held it in 1 quarter.
Point72 Middle East FZE's Humacyte position peaked at $6.74K in Q4 2022.
69 funds tracked by Wall St. Rank held Humacyte as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.